Wang Ruiying, Wang Min, He Shuaibing, Sun Guibo, Sun Xiaobo
Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
Front Pharmacol. 2020 Jun 9;11:872. doi: 10.3389/fphar.2020.00872. eCollection 2020.
Calcium homeostasis plays an essential role in maintaining excitation-contraction coupling (ECC) in cardiomyocytes, including calcium release, recapture, and storage. Disruption of calcium homeostasis may affect heart function, leading to the development of various heart diseases. Myocardial ischemia/reperfusion (MI/R) injury may occur after revascularization, which is a treatment used in coronary heart disease. MI/R injury is a complex pathological process, and the main cause of increased mortality and disability after treatment of coronary heart disease. However, current methods and drugs for treating MI/R injury are very scarce, not ideal, and have limitations. Studies have shown that MI/R injury can cause calcium overload that can further aggravate MI/R injury. Therefore, we reviewed the effects of critical calcium pathway regulators on MI/R injury and drew an intuitive diagram of the calcium homeostasis pathway. We also summarized and analyzed calcium pathway-related or MI/R drugs under research or marketing by searching Therapeutic Target and PubMed Databases. The data analysis showed that six drugs and corresponding targets are used to treat MI/R injury and involved in calcium signaling pathways. We emphasize the relevance of further detailed investigation of MI/R injury and calcium homeostasis and the therapeutic role of calcium homeostasis in MI/R injury, which bridges basic research and clinical applications of MI/R injury.
钙稳态在维持心肌细胞的兴奋-收缩偶联（ECC）中起着至关重要的作用，包括钙释放、再摄取和储存。钙稳态的破坏可能会影响心脏功能，导致各种心脏病的发生。心肌缺血/再灌注（MI/R）损伤可能在血管重建后发生，血管重建是冠心病的一种治疗方法。MI/R损伤是一个复杂的病理过程，也是冠心病治疗后死亡率和致残率增加的主要原因。然而，目前治疗MI/R损伤的方法和药物非常稀缺，不理想且有局限性。研究表明，MI/R损伤可导致钙超载，进而进一步加重MI/R损伤。因此，我们综述了关键钙途径调节剂对MI/R损伤的影响，并绘制了钙稳态途径的直观示意图。我们还通过检索治疗靶点和PubMed数据库，总结并分析了正在研究或上市的与钙途径相关或MI/R的药物。数据分析表明，有六种药物及相应靶点用于治疗MI/R损伤并涉及钙信号通路。我们强调进一步详细研究MI/R损伤和钙稳态的相关性以及钙稳态在MI/R损伤中的治疗作用，这架起了MI/R损伤基础研究和临床应用的桥梁。
